Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin201161699021296855
   PubMed Web of Science ®Google Scholar
• PecorelliSRevised FIGO staging for carcinoma of the vulva, cervix, and endometriumInt J Gynaecol Obstet200910510310419367689
   PubMed Web of Science ®Google Scholar
• YangLDoupleEBO’HaraJACrabtreeRAEastmanAEnhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell linesRadiat Res19951442302367480650
   PubMed Web of Science ®Google Scholar
• MarkmanMChemoradiation in the management of cervix cancer: current status and future directionsOncology20138424625023392268
   PubMed Web of Science ®Google Scholar
• BrockAPragerWBohmeRPohlmannSThe methods and results of simultaneous radiochemotherapy with carboplatin in advanced cervical carcinomasStrahlenther Onkol1994170264268 German8197548
   PubMedGoogle Scholar
• LeathCA3rdStraughnJMJrChemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trialsGynecol Oncol201312925125723280089
   PubMed Web of Science ®Google Scholar
• PerezRPCellular and molecular determinants of cisplatin resistanceEur J Cancer199834153515429893624
   PubMed Web of Science ®Google Scholar
• ShaoJZhouBChuBYenYRibonucleotide reductase inhibitors and future drug designCurr Cancer Drug Targets2006640943116918309
   PubMed Web of Science ®Google Scholar
• SmithBDKarpJERibonucleotide reductase: an old target with new potentialLeuk Res2003271075107612921942
   PubMed Web of Science ®Google Scholar
• JordheimLPSevePTredanODumontetCThe ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancerLancet Oncol20111269370221163702
   PubMed Web of Science ®Google Scholar
• HeinemannVXuYZChubbSInhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidineMol Pharmacol1990385675722233693
   PubMed Web of Science ®Google Scholar
• HuangPChubbSHertelLWGrindeyGBPlunkettWAction of 2′,2′-difluorodeoxycytidine on DNA synthesisCancer Res199151611061171718594
   PubMed Web of Science ®Google Scholar
• BraakhuisBJRuiz van HaperenVWWeltersMJPetersGJSchedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenograftsEur J Cancer199531A233523408652266
   PubMed Web of Science ®Google Scholar
• BurnettAFRomanLDGarciaAAMuderspachLIBraderKRMorrowCPA phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervixGynecol Oncol200076636610620443
   PubMed Web of Science ®Google Scholar
• BrewerCABlessingJANagourneyRAMcMeekinDSLeleSZweizigSLCisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupGynecol Oncol200610038538816271750
   PubMed Web of Science ®Google Scholar
• SteeperJRSteuartCDA rapid assay for CDP reductase activity in mammalian cell extractsAnal Biochem1970341231305440901
   PubMed Web of Science ®Google Scholar
• ShaoJZhouBZhuLDetermination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assayBiochem Pharmacol20056962763415670581
   PubMed Web of Science ®Google Scholar
• ShaoJZhouBZhuLIn vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductaseCancer Res2004641614729598
   PubMed Web of Science ®Google Scholar
• ChouTCMotzerRJTongYBoslGJComputerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol designJ Natl Cancer Inst199486151715247932806
   PubMed Web of Science ®Google Scholar
• KangMHWanZKangYHSpostoRReynoldsCPMechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivationJ Natl Cancer Inst200810058059518398104
   PubMedGoogle Scholar
• VilmarAGarcia-FoncillasJHuarrizMSantoni-RugiuESorensenJBRT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLCLung Cancer20127530631221996087
   PubMed Web of Science ®Google Scholar
• LiuXZhouBXueLRibonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancerClin Colorectal Cancer2007637438117311703
   PubMed Web of Science ®Google Scholar
• KimDJungWKooJSThe expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypesJ Korean Med Sci20112635235921394302
   PubMed Web of Science ®Google Scholar
• WangLMLuFFZhangSYYaoRYXingXMWeiZMOverexpression of catalytic subunit M2 in patients with ovarian cancerChin Med J (Engl)20121252151215622884145
   PubMed Web of Science ®Google Scholar
• KunosCARadivoyevitchTKresakAElevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancersInt J Gynecol Cancer2012221463146923051959
   PubMed Web of Science ®Google Scholar
• GautamALiZRBeplerGRRM1-induced metastasis suppression through PTEN-regulated pathwaysOncogene2003222135214212687015
   PubMed Web of Science ®Google Scholar
• MorikawaTMaedaDKumeHHommaYFukayamaMRibonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancerHistopathology20105788589221166702
   PubMed Web of Science ®Google Scholar
• MorikawaTHinoRUozakiHExpression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitroHum Pathol2010411742174820825972
   PubMed Web of Science ®Google Scholar
• LiuXLaiLWangXRibonucleotide reductase small subunit M2B prognoses better survival in colorectal cancerCancer Res2011713202321321415168
   PubMed Web of Science ®Google Scholar
• OkumuraHNatsugoeSYokomakuraNExpression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinomaClin Cancer Res2006123740374516778101
   PubMed Web of Science ®Google Scholar
• ScatchardKForrestJLFlubacherMCornesPWilliamsCChemotherapy for metastatic and recurrent cervical cancerCochrane Database Syst Rev201210CD00646923076924
   PubMed Web of Science ®Google Scholar
• HernándezPOliveraPDueñas-GonzalezAGemcitabine activity in cervical cancer cell linesCancer Chemother Pharmacol20014848849211800030
   PubMed Web of Science ®Google Scholar
• TermrungruanglertWTresukosolDVasuratnaASittisomwongTLertkhachonsukRSirisabyaNNeoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2Gynecol Oncol20059757658115863162
   PubMed Web of Science ®Google Scholar
• SmithJThoLMXuNGillespieDAThe ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancerAdv Cancer Res20101087311221034966
   PubMed Web of Science ®Google Scholar
• FurgasonJMBahassi elMTargeting DNA repair mechanisms in cancerPharmacol Ther201313729830823107892
   PubMed Web of Science ®Google Scholar
• KunosCARadivoyevitchTPinkJRibonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancersRadiat Res201017457458120954859
   PubMed Web of Science ®Google Scholar
• MoufarijMAPhillipsDRCullinaneCGemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell linesMol Pharmacol20036386286912644587
   PubMed Web of Science ®Google Scholar
• NasrFLChahineGYKattanJGGemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancerClin Breast Cancer2004511712215245614
   PubMedGoogle Scholar
• MonkBJSillMWMcMeekinDSPhase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol2009274649465519720909
   PubMed Web of Science ®Google Scholar